PhaseRx
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$11.69
-0.0
-0.46
10
PhaseRx, Inc. operates as a bio pharmaceutical company that develops a portfolio of mRNA products to correct inherited, life-threatening liver diseases in children. The firm's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The firm's i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The firm is headquartered in Seattle.
PhaseRx, Inc. operates as a bio pharmaceutical company that develops a portfolio of mRNA products to correct inherited, life-threatening liver diseases in children. The firm's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The firm's i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The firm is headquartered in Seattle.
Recently from Cashu
Couldn't load Cashu news
Something went wrong. Try refreshing the page.